ARM
BSX icon

Adirondack Research & Management’s Boston Scientific BSX Stock Holding History

Adirondack Research & Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$381K Sell
8,780
-310
-3% -$13.7K 0.46% 80
2021
Q2 		$389K Sell
9,090
-115
-1% -$4.84K 0.46% 73
2021
Q1 		$356K Hold
9,205
– – 0.42% 73
2020
Q4 		$331K Hold
9,205
– – 0.45% 65
2020
Q3 		$352K Hold
9,205
– – 0.49% 55
2020
Q2 		$323K Sell
9,205
-30
-0.3% -$1.08K 0.42% 55
2020
Q1 		$301K Sell
9,235
-510
-5% -$19.9K 0.42% 58
2019
Q4 		$441K Sell
9,745
-3,920
-29% -$164K 0.38% 62
2019
Q3 		$556K Hold
13,665
– – 0.49% 61
2019
Q2 		$587K Hold
13,665
– – 0.42% 63
2019
Q1 		$524K Sell
13,665
-600
-4% -$22.9K 0.33% 71
2018
Q4 		$504K Sell
14,265
-50
-0.3% -$1.81K 0.32% 66
2018
Q3 		$551K Hold
14,315
– – 0.21% 83
2018
Q2 		$471K Hold
14,315
– – 0.18% 86
2018
Q1 		$391K Sell
14,315
-1,990
-12% -$54.1K 0.16% 96
2017
Q4 		$404K Hold
16,305
– – 0.16% 94
2017
Q3 		$476K Hold
16,305
– – 0.19% 84
2017
Q2 		$452K Hold
16,305
– – 0.18% 86
2017
Q1 		$406K Hold
16,305
– – 0.15% 96
2016
Q4 		$353K Hold
16,305
– – 0.12% 97
2016
Q3 		$388K Hold
16,305
– – 0.14% 93
2016
Q2 		$381K Sell
16,305
-16,320
-50% -$353K 0.14% 94
2016
Q1 		$614K Sell
32,625
-1,000
-3% -$17.6K 0.22% 76
2015
Q4 		$620K Sell
33,625
-400
-1% -$7.17K 0.22% 74
2015
Q3 		$558K Sell
34,025
-3,075
-8% -$52.6K 0.21% 77
2015
Q2 		$657K Sell
37,100
-2,100
-5% -$37.5K 0.24% 71
2015
Q1 		$696K Buy
39,200
+500
+1% +$7.9K 0.27% 68
2014
Q4 		$513K Sell
38,700
-125
-0.3% -$1.6K 0.19% 81
2014
Q3 		$459K Sell
38,825
-2,500
-6% -$31.5K 0.17% 85
2014
Q2 		$528K Sell
41,325
-650
-2% -$8.45K 0.18% 86
2014
Q1 		$568K Sell
41,975
-1,250
-3% -$16.4K 0.22% 82
2013
Q4 		$520K Sell
43,225
-17,900
-29% -$211K 0.25% 81
2013
Q3 		$718K Sell
61,125
-3,000
-5% -$32.5K 0.41% 74
2013
Q2 		$594K Buy
+64,125
New +$544K 0.44% 71

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return

Adirondack Research & Management's BSX Position: Q3 2021 in Review

Adirondack Research & Management reduced its Boston Scientific (BSX) stake by 3.4% in Q3 2021, selling an estimated $13.7K and leaving 8,780 shares worth $381K. The position accounts for 0.46% of the portfolio, ranked #80.

Adirondack Research & Management first reported a position in BSX in Q2 2013 and has held it in 34 quarters since. The position peaked at $718K in Q3 2013. 879 funds tracked by Wall St. Rank hold BSX as of Q3 2021.

  • Adirondack Research & Management held 8,780 shares of Boston Scientific worth $381K as of Q3 2021.
  • Adirondack Research & Management sold 310 Boston Scientific shares in Q3 2021, an estimated $13.7K.
  • Boston Scientific made up 0.46% of Adirondack Research & Management's portfolio in Q3 2021, its #80 holding.
  • Adirondack Research & Management first reported a position in Boston Scientific in Q2 2013 and has held it in 34 quarters since.
  • Adirondack Research & Management's Boston Scientific position peaked at $718K in Q3 2013.
  • 879 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2021.

Based on Adirondack Research & Management's 13F filing for Q3 2021, filed 29 Oct 2021.